Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Medtronic PLC, solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Medtronic PLC debt to equity ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Medtronic PLC debt to capital ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Medtronic PLC debt to assets ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Medtronic PLC financial leverage ratio increased from Q4 2024 to Q1 2025 but then slightly decreased from Q1 2025 to Q2 2025. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Medtronic PLC interest coverage ratio deteriorated from Q4 2024 to Q1 2025 but then improved from Q1 2025 to Q2 2025 not reaching Q4 2024 level. |
Debt to Equity
Medtronic PLC, debt to equity calculation (quarterly data)
| Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 3,719) | 1,553) | 1,092) | 1,029) | 1,339) | 519) | 20) | 5,918) | 5,864) | 5,729) | 3,742) | 865) | 16) | 6) | 11) | 3,821) | 4,041) | 5,823) | 2,776) | 844) | 875) | 1,458) | 838) | 1,356) | 1,343) | 1,545) | ||||||||
| Long-term debt | 24,607) | 26,312) | 23,932) | 24,153) | 23,741) | 24,463) | 24,344) | 22,210) | 20,753) | 17,481) | 20,372) | 24,290) | 25,607) | 25,958) | 26,378) | 26,502) | 25,967) | 22,867) | 22,021) | 24,732) | 24,752) | 24,804) | 24,486) | 23,674) | 23,673) | 23,678) | ||||||||
| Total debt | 28,326) | 27,865) | 25,024) | 25,182) | 25,080) | 24,982) | 24,364) | 28,128) | 26,617) | 23,210) | 24,114) | 25,155) | 25,623) | 25,964) | 26,389) | 30,323) | 30,008) | 28,690) | 24,797) | 25,576) | 25,627) | 26,262) | 25,324) | 25,030) | 25,016) | 25,223) | ||||||||
| Shareholders’ equity | 48,494) | 47,947) | 50,214) | 51,792) | 51,460) | 51,178) | 51,483) | 51,441) | 51,880) | 52,672) | 52,551) | 52,542) | 51,991) | 51,486) | 51,428) | 50,758) | 50,164) | 50,296) | 50,737) | 51,808) | 50,578) | 50,363) | 50,091) | 49,829) | 49,607) | 50,224) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to equity1 | 0.58 | 0.58 | 0.50 | 0.49 | 0.49 | 0.49 | 0.47 | 0.55 | 0.51 | 0.44 | 0.46 | 0.48 | 0.49 | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 0.38 | 0.38 | 0.38 | 0.38 | 0.41 | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | 0.58 | 0.60 | 0.61 | 0.62 | ||||||||
| Cigna Group | — | — | — | 0.78 | 0.77 | 0.80 | 0.67 | 0.68 | 0.72 | 0.73 | 0.69 | 0.70 | 0.73 | 0.72 | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | 0.83 | 0.87 | 0.89 | 0.95 | ||||||||
| CVS Health Corp. | — | — | — | 0.87 | 0.89 | 0.87 | 0.81 | 0.83 | 0.88 | 0.82 | 0.74 | 0.74 | 0.73 | 0.76 | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | 1.07 | 1.10 | 1.16 | 1.25 | ||||||||
| Elevance Health Inc. | — | — | — | 0.62 | 0.66 | 0.65 | 0.64 | 0.65 | 0.66 | 0.68 | 0.66 | 0.66 | 0.66 | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | 0.63 | 0.65 | 0.63 | 0.64 | ||||||||
| Intuitive Surgical Inc. | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| UnitedHealth Group Inc. | — | — | — | 0.83 | 0.84 | 0.85 | 0.70 | 0.75 | 0.80 | 0.87 | 0.74 | 0.65 | 0.71 | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 | ||||||||
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 28,326 ÷ 48,494 = 0.58
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Medtronic PLC debt to equity ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
Debt to Capital
Medtronic PLC, debt to capital calculation (quarterly data)
| Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 3,719) | 1,553) | 1,092) | 1,029) | 1,339) | 519) | 20) | 5,918) | 5,864) | 5,729) | 3,742) | 865) | 16) | 6) | 11) | 3,821) | 4,041) | 5,823) | 2,776) | 844) | 875) | 1,458) | 838) | 1,356) | 1,343) | 1,545) | ||||||||
| Long-term debt | 24,607) | 26,312) | 23,932) | 24,153) | 23,741) | 24,463) | 24,344) | 22,210) | 20,753) | 17,481) | 20,372) | 24,290) | 25,607) | 25,958) | 26,378) | 26,502) | 25,967) | 22,867) | 22,021) | 24,732) | 24,752) | 24,804) | 24,486) | 23,674) | 23,673) | 23,678) | ||||||||
| Total debt | 28,326) | 27,865) | 25,024) | 25,182) | 25,080) | 24,982) | 24,364) | 28,128) | 26,617) | 23,210) | 24,114) | 25,155) | 25,623) | 25,964) | 26,389) | 30,323) | 30,008) | 28,690) | 24,797) | 25,576) | 25,627) | 26,262) | 25,324) | 25,030) | 25,016) | 25,223) | ||||||||
| Shareholders’ equity | 48,494) | 47,947) | 50,214) | 51,792) | 51,460) | 51,178) | 51,483) | 51,441) | 51,880) | 52,672) | 52,551) | 52,542) | 51,991) | 51,486) | 51,428) | 50,758) | 50,164) | 50,296) | 50,737) | 51,808) | 50,578) | 50,363) | 50,091) | 49,829) | 49,607) | 50,224) | ||||||||
| Total capital | 76,820) | 75,812) | 75,238) | 76,974) | 76,540) | 76,160) | 75,847) | 79,569) | 78,497) | 75,882) | 76,665) | 77,697) | 77,614) | 77,450) | 77,817) | 81,081) | 80,172) | 78,986) | 75,534) | 77,384) | 76,205) | 76,625) | 75,415) | 74,859) | 74,623) | 75,447) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to capital1 | 0.37 | 0.37 | 0.33 | 0.33 | 0.33 | 0.33 | 0.32 | 0.35 | 0.34 | 0.31 | 0.31 | 0.32 | 0.33 | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 0.27 | 0.27 | 0.27 | 0.28 | 0.29 | 0.31 | 0.31 | 0.31 | 0.32 | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | 0.37 | 0.38 | 0.38 | 0.38 | ||||||||
| Cigna Group | — | — | — | 0.44 | 0.44 | 0.44 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.41 | 0.42 | 0.42 | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | 0.45 | 0.46 | 0.47 | 0.49 | ||||||||
| CVS Health Corp. | — | — | — | 0.47 | 0.47 | 0.46 | 0.45 | 0.45 | 0.47 | 0.45 | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | 0.52 | 0.52 | 0.54 | 0.56 | ||||||||
| Elevance Health Inc. | — | — | — | 0.38 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.40 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | ||||||||
| Intuitive Surgical Inc. | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| UnitedHealth Group Inc. | — | — | — | 0.45 | 0.46 | 0.46 | 0.41 | 0.43 | 0.44 | 0.46 | 0.43 | 0.39 | 0.41 | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 | ||||||||
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= 28,326 ÷ 76,820 = 0.37
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Medtronic PLC debt to capital ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
Debt to Assets
Medtronic PLC, debt to assets calculation (quarterly data)
| Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 3,719) | 1,553) | 1,092) | 1,029) | 1,339) | 519) | 20) | 5,918) | 5,864) | 5,729) | 3,742) | 865) | 16) | 6) | 11) | 3,821) | 4,041) | 5,823) | 2,776) | 844) | 875) | 1,458) | 838) | 1,356) | 1,343) | 1,545) | ||||||||
| Long-term debt | 24,607) | 26,312) | 23,932) | 24,153) | 23,741) | 24,463) | 24,344) | 22,210) | 20,753) | 17,481) | 20,372) | 24,290) | 25,607) | 25,958) | 26,378) | 26,502) | 25,967) | 22,867) | 22,021) | 24,732) | 24,752) | 24,804) | 24,486) | 23,674) | 23,673) | 23,678) | ||||||||
| Total debt | 28,326) | 27,865) | 25,024) | 25,182) | 25,080) | 24,982) | 24,364) | 28,128) | 26,617) | 23,210) | 24,114) | 25,155) | 25,623) | 25,964) | 26,389) | 30,323) | 30,008) | 28,690) | 24,797) | 25,576) | 25,627) | 26,262) | 25,324) | 25,030) | 25,016) | 25,223) | ||||||||
| Total assets | 90,042) | 89,749) | 89,981) | 90,836) | 90,087) | 90,776) | 90,948) | 94,134) | 93,241) | 89,914) | 90,981) | 91,804) | 91,756) | 91,802) | 93,083) | 97,270) | 95,886) | 93,906) | 90,689) | 92,822) | 91,053) | 91,268) | 89,694) | 88,730) | 88,150) | 89,721) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to assets1 | 0.31 | 0.31 | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 0.20 | 0.20 | 0.20 | 0.20 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | ||||||||
| Cigna Group | — | — | — | 0.21 | 0.21 | 0.21 | 0.20 | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | 0.24 | 0.25 | 0.25 | 0.26 | ||||||||
| CVS Health Corp. | — | — | — | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 | 0.24 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | 0.31 | 0.31 | 0.33 | 0.34 | ||||||||
| Elevance Health Inc. | — | — | — | 0.23 | 0.25 | 0.24 | 0.23 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | 0.26 | 0.26 | 0.25 | 0.26 | ||||||||
| Intuitive Surgical Inc. | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| UnitedHealth Group Inc. | — | — | — | 0.26 | 0.26 | 0.26 | 0.23 | 0.22 | 0.23 | 0.25 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 | ||||||||
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= 28,326 ÷ 90,042 = 0.31
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Medtronic PLC debt to assets ratio deteriorated from Q4 2024 to Q1 2025 and from Q1 2025 to Q2 2025. |
Financial Leverage
Medtronic PLC, financial leverage calculation (quarterly data)
| Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Total assets | 90,042) | 89,749) | 89,981) | 90,836) | 90,087) | 90,776) | 90,948) | 94,134) | 93,241) | 89,914) | 90,981) | 91,804) | 91,756) | 91,802) | 93,083) | 97,270) | 95,886) | 93,906) | 90,689) | 92,822) | 91,053) | 91,268) | 89,694) | 88,730) | 88,150) | 89,721) | ||||||||
| Shareholders’ equity | 48,494) | 47,947) | 50,214) | 51,792) | 51,460) | 51,178) | 51,483) | 51,441) | 51,880) | 52,672) | 52,551) | 52,542) | 51,991) | 51,486) | 51,428) | 50,758) | 50,164) | 50,296) | 50,737) | 51,808) | 50,578) | 50,363) | 50,091) | 49,829) | 49,607) | 50,224) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Financial leverage1 | 1.86 | 1.87 | 1.79 | 1.75 | 1.75 | 1.77 | 1.77 | 1.83 | 1.80 | 1.71 | 1.73 | 1.75 | 1.76 | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 1.87 | 1.86 | 1.87 | 1.90 | 1.92 | 1.97 | 1.99 | 2.03 | 2.04 | 2.03 | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | 2.18 | 2.15 | 2.16 | 2.19 | ||||||||
| Cigna Group | — | — | — | 3.74 | 3.76 | 3.72 | 3.30 | 3.28 | 3.30 | 3.33 | 3.21 | 3.20 | 3.33 | 3.31 | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | 3.44 | 3.46 | 3.52 | 3.64 | ||||||||
| CVS Health Corp. | — | — | — | 3.37 | 3.37 | 3.38 | 3.27 | 3.38 | 3.44 | 3.35 | 3.21 | 3.27 | 3.06 | 3.15 | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | 3.48 | 3.52 | 3.57 | 3.68 | ||||||||
| Elevance Health Inc. | — | — | — | 2.66 | 2.68 | 2.76 | 2.77 | 2.88 | 2.86 | 2.92 | 2.83 | 2.86 | 2.82 | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | 2.44 | 2.48 | 2.46 | 2.48 | ||||||||
| Intuitive Surgical Inc. | — | — | — | 1.14 | 1.13 | 1.13 | 1.16 | 1.17 | 1.17 | 1.16 | 1.17 | 1.15 | 1.14 | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | ||||||||
| UnitedHealth Group Inc. | — | — | — | 3.17 | 3.20 | 3.28 | 3.08 | 3.34 | 3.40 | 3.49 | 3.16 | 3.26 | 3.16 | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 | ||||||||
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 90,042 ÷ 48,494 = 1.86
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Medtronic PLC financial leverage ratio increased from Q4 2024 to Q1 2025 but then slightly decreased from Q1 2025 to Q2 2025. |
Interest Coverage
Medtronic PLC, interest coverage calculation (quarterly data)
| Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Net income attributable to Medtronic | 1,270) | 1,042) | 654) | 1,322) | 909) | 791) | 1,180) | 1,222) | 427) | 929) | 1,485) | 1,480) | 1,311) | 763) | 1,360) | 1,270) | 489) | 487) | 646) | 1,915) | 1,364) | 864) | 1,172) | 1,269) | 1,115) | 1,075) | ||||||||
| Add: Net income attributable to noncontrolling interest | 8) | 7) | 6) | 15) | 2) | 6) | 9) | 7) | 8) | 2) | 8) | 3) | 6) | 6) | 6) | 9) | 5) | 4) | (7) | 4) | 7) | 13) | 10) | 2) | 5) | 2) | ||||||||
| Add: Income tax expense | 281) | 219) | 196) | 135) | 402) | 399) | 361) | 146) | 960) | 113) | 109) | 106) | 176) | 64) | 200) | (59) | 31) | 93) | (434) | (340) | (77) | 100) | 110) | 99) | 235) | 103) | ||||||||
| Add: Interest expense, net | 209) | 167) | 203) | 188) | 180) | 148) | 187) | 167) | 118) | 164) | 143) | 137) | 136) | 137) | 141) | 143) | 470) | 171) | 162) | 156) | 165) | 609) | 718) | 243) | 241) | 242) | ||||||||
| Earnings before interest and tax (EBIT) | 1,768) | 1,435) | 1,059) | 1,660) | 1,493) | 1,344) | 1,737) | 1,542) | 1,513) | 1,208) | 1,745) | 1,726) | 1,629) | 970) | 1,707) | 1,363) | 995) | 755) | 367) | 1,735) | 1,459) | 1,586) | 2,010) | 1,613) | 1,596) | 1,422) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Interest coverage1 | 7.72 | 7.65 | 7.73 | 8.87 | 8.97 | 9.90 | 9.43 | 10.15 | 11.02 | 10.88 | 10.98 | 10.95 | 10.18 | 5.65 | 5.21 | 3.68 | 4.02 | 6.60 | 4.71 | 4.12 | 3.84 | 3.76 | 4.60 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 12.65 | 11.74 | 11.46 | 11.46 | 10.79 | 11.34 | 13.06 | 15.89 | 18.41 | 20.07 | 18.10 | 16.41 | 16.38 | 14.28 | 12.77 | 10.10 | 7.66 | 6.80 | 7.39 | 7.09 | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | 3.33 | 4.41 | 4.55 | 5.20 | 5.59 | 2.71 | 3.43 | 3.46 | 2.75 | 5.49 | 5.27 | 5.16 | 4.92 | 4.60 | 4.52 | 4.36 | 4.67 | 4.76 | 4.29 | 3.96 | — | — | — | ||||||||
| Elevance Health Inc. | — | — | — | 8.52 | 9.07 | 8.70 | 8.49 | 8.87 | 9.76 | 9.95 | 10.13 | 10.75 | 10.71 | 11.01 | 10.93 | 10.04 | 8.03 | 9.09 | 8.96 | 9.59 | 11.16 | 9.14 | 9.02 | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | 6.39 | 6.79 | 7.53 | 9.97 | 10.21 | 10.99 | 12.25 | 13.59 | 14.66 | 14.45 | 14.26 | 14.44 | 13.46 | 13.03 | 14.88 | 13.47 | 14.12 | 13.89 | 11.40 | 11.55 | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26), 10-K (reporting date: 2019-04-26), 10-Q (reporting date: 2019-01-25), 10-Q (reporting date: 2018-10-26), 10-Q (reporting date: 2018-07-27).
1 Q2 2025 Calculation
Interest coverage
= (EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024)
÷ (Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024)
= (1,768 + 1,435 + 1,059 + 1,660)
÷ (209 + 167 + 203 + 188)
= 7.72
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Medtronic PLC interest coverage ratio deteriorated from Q4 2024 to Q1 2025 but then improved from Q1 2025 to Q2 2025 not reaching Q4 2024 level. |